chemoprophylaxis
proven
registers
taken
detoxification
london
pyrimeth
chittagong
lets
alex
medicine
shown
af
excluded
retrovirals
mi
mefloquine
2203
spellings
fh
contributions
malar
obstetric
address
rbm
me
1259
dq
advise
sient
chondroitin
2002
sheets
jo
option
death
regi
eur
headache
savigny
appropriate
rate
ran
dence
duffy
teratogenic
treated
vaules
quinacrine
pukrittayakamee
outcome
synthase
perre
pp
573
carneiro
jh
safest
chlo
506
extensively
show
reducing
mshinda
nd
afr
sufficient
hydrochloride
581
kramer
lack
sac
ltd
27709
keppel
partum
immediately
acceptance
challenges
ance
dj
artemether
652
viewed
csa
serious
chougnet
keep
better
jl
yours
272
775
oguntove
2518
em
final
toxicol
ao
trimester
excess
294
sci
already
lethality
concepts
kawuondo
432
fr
drugs
missi
arms
zhi
maradit
112
falade
191
lowe
unstable
rent
262
primarily
haem
table
milk
green
526
grammes
exposure
nct00344006
partner
spiegel
207
delay
mushi
burden
inte
descriptive
references
wa
fering
xp
tial
agent
humoral
659
tt
fusai
white
capture
could
128
rates
postpartum
susceptible
travelers
yeung
overbosch
reticulum
1843
sanofi
cv
coordination
formulate
sulfadox
wirima
research
matern
eliminated
scrutinized
sion
ja
425
gg
procedures
birth
both
disseminating
icy
pharmacokinetics
licensee
532
male
nct00146731
395
afro
trop
rev
prior
mainly
embryo
sigma
peak
would
puerperal
administered
cmc_upload
chimpeni
bennett
significantly
184
181
ghana
stillbirth
issifou
global
yameogo
horton
ilett
adipose
recommendation
nat
third
premature
mortality
orton
senting
perinatal
argaw
kenya
1289
paediatric
ence
erability
467
larium
intramuscularly
childbearing
diaminodiphenylsulfone
cd004912
jones
efficacy
sug
305
prevention
enter
prophylaxis
rather
district
age
proux
cure
recommended
reduces
volume
higher
ar
draft
van
results
lence
late
fried
key
antimalarial
plan
pared
whitty
tjitra
yolk
temisinin
appear
1773
area
hope
embryotox
piperaquine
chemother
735
four
robertson
sarcoplasmic
novartis
selective
fievet
1133
recommendations
tk
bing
davis
experience
holleykin
entire
who
topic
ruengweerayut
heikkinen
plasma
simple
bloland
grobusch
1094
bwika
emerging
routine
laboratories
database
primigravidae
365
hill
phillips
bounyasong
implausibility
failure
factors
institutions
partnership
expected
near
leading
eases
consultations
1998
sexually
pre
breman
kimani
studies
105
silent
111
chloroquine
action
marchant
bmj
roskell
many
causal
fat
molyneux
victora
antimalarials
richie
truong
bur
tanzania
abortion
activities
author
kili
walraven
widespread
act
gral
mq
exact
chlorproguanil
provide
fonck
way
129
fol
124
implications
graya
identified
phaiphun
ramharter
baiden
succeed
patient
presented
possibility
595
rl
vanijanonta
southern
113
gmail
cameroon
natal
oestrogen
volun
variety
ests
alone
little
ated
combination
emptying
chitsulo
underway
models
mkandala
axial
artekinpr304
ringwald
chalermarut
mas3
combina
uncertainty
813
regimen
suphajaisiddhi
peutic
tab
koram
antimalar
brockman
original
increase
von
sec
soc
dihydrofolate
dehydro
mal
arte
manera
suggested
doi
2001
adoxine
aids
published
chirachariyavej
tive
nduati
months
preg
widely
later
derivative
poravuth
1400
ganjar
colvin
containing
modium
ra
obiero
iron
cost
biological
dium
under
contrast
hygiene
kayentao
thromycin
molecular
mycin
azi
our
ilesanmi
earlier
its
ngwawe
462
fk
group
accessed
ine
mice
milhous
toxicity
aminoquinoline
accepted
dzinjalamala
ua
469
635
medical
soon
192
vomiting
sti
kc
dp
reliable
genase
placebo
than
fever
603
effective
hepatic
jgl
vugt
233
indonesian
perennial
combines
qui
reviews
inf
plicated
living
thea
tional
follow
kamwendo
changalucha
hoogstrate
rapid
brian
micek
sulo
2000
hewitt
mediated
resistance
char
narrow
who_sp_statement
ln
underlying
order
interactions
bio
bruce
following
data
northeast
faye
confronting
acterized
labour
131
intravascular
cochrane
after
tran
gilveray
1502
dorman
amodiaquine
back
nant
dunne
namics
india
difference
embase
1997
1680
mermin
plans
andersen
braitman
assessment
child
vietnam
organizations
tracts
licensed
cin
chen
770
ipti
1990's
nigeria
pongtavornpinyo
new
evaluation
centre
roberts
org
jersey
uterine
reviewed
respectively
needed
develop
stepniewska
undermined
1685
maung
affordable
carriage
2541
prospective
experienced
doxy
bednets
draogo
expensive
cited
miller
liminary
senegal
your
nagelkerke
start
holoendemic
2009
micronutrient
complexes
differ
dihydroartemsinin
haemoglobin
371
profile
resulted
discussions
actually
karim
1990
special
structurally
guanil
criteria
quickening
1960's
preva
mehta
escalation
antenatal
erythromycin
179
acquired
compared
epidemic
rats
ashley
colleagues
gambian
combinations
did
sidered
extensive
hutchinson
harrell
benin
soldiers
any
blinded
aminoquinilones
more
cross
subjects
hien
prolapse
patterns
prophylactic
sweet
141
groups
chongqing
buhta
persistence
schultz
report
geogr
denis
operational
most
900
had
information
venture
rier
lbw
triangular
tr
curr
sf
developmental
godwin
mwita
bination
forming
alloueche
cs
asia
transmitted
relevant
lim
phase
much
part
fa
tively
iii
icity
lifetime
seen
drug
upon
only
sowunmi
758
236
gates
594
chong
fandeur
aust
proceedings
chai
blind
cutts
jama
nzila
1000
193
hatcher
park
119
biomed
ber
producing
devel
publishing_adv
lished
sustained
malarial
fal
ald
into
seven
gm
good
aw
west
isolates
knobloch
systematic
particu
maclean
formu
roll
state
tal
6750
probably
144
nct00331136
john
delayed
1349
agbo
associated
kheir
fogstad
aap
lansen
pinder
conception
uganda
increasing
lapdap
conversely
wm
trape
da
come
file
preparation
curing
brentlinger
least
less
parasitology
1993
1469
newman
analysis
eurartekin
subsidized
nothdurft
introduction
tall
fixed
thanh
paper
received
prescribing
monotherapies
update
next
todd
fanisdar
110
schnieder
value
oral
socheat
biomedcentral
availa
faso
cheaper
transplacental
attending
science
mr
benga
anti
dystocia
randal
ob
kolczak
pharmacol
rat
adults
secondary
applied
antigens
tafenoquine
some
advantages
unrestricted
graham
immunodeficiency
evi
conquering
barton
ahead
non
ds
aquine
against
sis
delmont
label
benefits
needs
focus
provinces
tolerability
stationed
feasibility
adherence
ability
simi
dubois
likely
shorter
102
greenwood2
burkina
nutley
1218
berman
detected
obstet
dm
salhan
20afro
adjustment
barret
endemic
levels
infant
rapidly
se
fehintola
serwadda
recom
com
modeling
multicentre
chloro
mwanza
intense
creative
healthy
pregnant
wawerd
parasitol
kenyan
gynecol
product
9511
necessitated
consider
saharan
rh
rogier
course
1970's
mills
lower
mitochondrial
612
specific
1391
picarima
insecticide
design
214
ter
interests
inhibition
2539
gabon
marsh
eyers
mur
infect
orally
occurred
involved
pj
other
sul
328
transient
licenses
1223
kun
oxford
except
733
university
morphological
what's
kigozib
another
rr
wilairatana
unrecognized
1474
target
mordmuller
fryauff
125
northwest
senegalese
tries
osting
formation
714
thera
unavailable
oo
ge
babaniyi
ann
chemosuppressive
ogasawara
parise
organ
aventis
7ht
morbidity
frobert
ladner
186
jy
artemisinins
1986
pharmacovigilance
impairment
reports
cot
plowe
insufficient
kuaha
sex
dba
office
well
2555
resorption
recent
preventing
dorsey
bangali
institutes
potential
olliaro
evans
cellular
iptp
none
followed
analogues
nutrition
acts
decide
kf
coun
470
indicating
dth
suitable
tiveness
pcr
dt
cohort
world
hospital
ce
emergency
864
syst
early
databases
trade
lisa
hematin
tana
196
nancy
118
gl
nakata
seasonal
unique
194
stillbirths
1021
1989
being
cds
ek
4th
ongoing
costs
various
servicewomen
oosting
faiz
derived
man
slutsker
rela
clini
pubmed
833
copyright
july
548
http
leroy
1110
1999
duombo
rouamba
shaw
pdf
may
archived
different
emergence
wilkinson
cg
terms
mid
kazembe
lized
364
novel
consensus
tanga
bailey
1992
andrew
saudi
ag
sg
infec
lev
mcgready
uncompli
int
number
okeyeh
ea
mosnier
attempted
organization
lumefantrine
comparative
relevance
intrauterine
now
southeast
population
test
coastal
alilio
resist
artemisi
silchamroon
100
300
how
their
colonization
best
drafted
nurse
therefore
having
writer
slowly
included
asymptomatic
235
265
antibiotic
jaffar
tanzanian
elimination
mazue
2london
carried
makes
animals
tablet
also
582
distribution
related
manyando
cancer
consultation
but
ps
over
reaching
largely
keo
tenuous
agreement
pub
prevent
improving
1746
jv
isoenzyme
statistical
makori
mmv
citation
590
artemesinins
undertaken
ha
include
hamer
suppression
unlikely
papers
evidence
mulenga
126
zupan
jc
2875
cho
651
176
emeka
krudsood
428
allows
worldwide
500
sir
prevents
based
knirsch
cycline
elective
conflict
zidovudine
assigned
632
favourable
rural
rolling
harrison
roquine
complications
2197
peters
made
page
pri
chemo
field
1005
greater
such
ticide
borderline
kd
leowat
artekin
equivalent
826
jn
current
intakes
hesran
example
discussed
virus
erbate
schuster
tme
choices
north
assessed
alternatives
intolerable
combining
wabwire
programme
abdalla
candidates
elevated
gametocyte
ward
time
maintain
evaluate
murray
ment
combi
aleman
publications
sokhna
dummy
409
son
human
585
twice
evaluating
chinese
framework
nct00131235
1national
cal
hills
adegnika
pa
neonatal
wj
cell
nine
dren
feng
bibliographic
roussilhon
fuchs
jima
bernard
showed
international
wilairat
mberu
represent
has
2007
103
raasveld
stis
clercq
barends
synergy
alwaseila
days
schilthuis
750
birthweight
alter
coordinated
elbashir
im
continue
dl
kakamega
dif
use
effi
week
despite
assoc
retrospective
uncomplicated
azithro
bdra
minutes
1750
343
pricing
box
roly
therapy
pan
con
conference
cambodian
tetracycline
vivax
charge
events
spontaneous
muga
ks
acta
lutalob
threatened
whilst
zanoncelli
maculopapular
safe
nin
subsequently
randomized
establish
observed
growth
subregional
excretion
established
complication
mbuya
searching
mean
bulmer
endoplasmic
baruah
surveillance
1475
nct00316329
inc
simonon
range
abortions
medium
133
deloron
particularly
effect
beta
transmission
cau
keli
tolerated
mathai
declined
menen
search
exac
formulations
inhibits
broek
466
lay
myometrial
abstract
reprod
issues
primary
agyei
acknowledgements
falci
above
combined
185
snow
mukasa
excreted
sp
reeder
lege
127
manufacturers
lactam
monotherapy
lowing
elimina
administra
trans
email
lehesran
modest
summarizes
facts
withdrawal
sulfate
inexpensive
writ
targeting
debated
molecule
regional
andrews
verified
reduce
access
za
land
101
intrapartum
breast
activity
skeleton
daries
thank
type
285
sequestration
context
thwai
nk
there
gd
mended
larial
schizontocide
391
thailand
cord
western
pharma
south
quinine
phophak
khoromana
falciparum
narauin
dap
var
readily
bg
info
anemia
meeting
chimsuku
china
dis
ali
moreira
116
inter
few
authors
mukadam
york
gests
responses
001
researc
ious
african
should
karunajeewa
zongo
301
compounds
domised
parum
tinnitus
selected
ity
atovaquone
bar
streptococci
confounders
pol
plas
interscience
poor
pharmaceuticals
dur
therapies
phosphate
men
schellenberg
hallett
clinical
properly
chopra
pb
phadoxine
multidrug
badiaga
dez
860
cb
treating
moller
sambou
undiagnosed
323
laine
unclear
545
rastogi
erhart
pm
additional
187
trimesters
director
pyronaridine
moran
haematin
biomedical
cri
falciparm
ellis
mammals
line
vacuole
108
abuaku
villegas
477
result
kl
registration
360
text
ekblad
findings
muheza
stated
quine
gov
detail
plus
tesfaye
aminoacridine
need
persist
binka
353
lariam
dc
outside
per
fewer
young
shulman
maquine
trials
1990s
2200
working
donders
metabolism
539
difficult
indicated
mm
sheng
power
period
although
nou
important
mangenc
lw
comparison
inaccessible
tanaprapin
all
periods
1476
ka
riamet
bickii
bogearts
doxycycline
clinicaltri
vallely1
2006
awine
adolescents
effec
admission
milet
202
total
coartem
ences
development
support
submit
gv
factor
parasite
kigali
potent
control
including
laborato
car
1462
maelankiri
mj
wr
february
complete
chandramo
content
malaria
artemisinin
bm
hours
schwarz
impair
foetal
historic
brandling
wood
ries
mw
867
boulanger
during
altered
mester
willingmyre
cases
rosenthal
315
basco
methods
1504
recently
domly
otieno
q7
moses
strenuous
holley
fetal
ww
distributed
sus
geus
informal
unnecessary
fe
pharmacokinetic
portfolio
1186
attribution
open
significant
lh
miscarriage
participated
forms
dihydroar
han
rogers
pradines
nam
designed
predict
post
808
oyakhirome
comes
mens
cacy
efficacious
alexander
they
kamal
inhibitor
adverse
636
conferred
117
sewankamboc
prematurity
garner
aj
aa
clinic
ronald
region
monthly
options
suggest
manufacturer
macdon
mycoplasma
je
urealyticum
plos
metabolizing
indonesia
sullivana
atovoquone
antima
dapsone
1863
alternative
ante
cq
effects
ns
1480
multi
date
median
assam
papua
reasonably
life
mensah
larly
subject
hd
antibiotics
marketing
846
symptoms
roche
system
month
steketee
simpson
teers
greenwood
das
every
enrolled
contra
domized
emembolu
model
bly
img
tang
appears
national
attenders
ma
policy
terminations
exp
addition
gs
sulfadoxine
risk
brand
care
ranque
1015
367
luxemburger
976
permits
inhibited
accidental
slow
highly
similarly
benefit
study
yahoo
africa's
arm
bile
488
chemotherapy
clark
outcomes
342
unchanged
case
rabbits
reassess
malorone
untreated
slight
deaths
observation
effectively
safely
facliparum
pharmaceutical
20harare
mass
about
sites
articles
120
metabolite
taylor
amine
hinder
calcium
inappropriate
hutagalung
toxic
sulphate
medhin
together
concur
heymann
lar
lawson
episodes
animal
1143
technical
congenital
trace
200
zhongguo
east
ipt
chilima
109
av
cheap
gb
verhoeff
molar
competing
active
glucose
urgently
impact
premji
formulation
mesinin
vitamin
viet
mon
interacts
erythrocytes
liu
migot
bienzle
lin
prevalence
db
oa
triangle
cortisol
currently
jilo
med
conceived
lankoande
yei
added
mckenzie
amodi
pyrimethamine
coarsucam
remains
provided
large
cooke
relatively
1299
counties
322
owusu
cc
kaul
chemical
treatment
thai
nation
types
mether
long
commons
seidlein
hyg
nolly
rabbit
nate
suppl
clinicaltrials
become
initial
glaxosmithkline
ent
took
cowan
pregnancy
malle
central
plasodium
seems
ahmed
consideration
dihydroartemisinin
tion
kapur
ciparum
several
adam
chil
dihyroarte
akinyinka
achiano
caution
comparable
mohrle
lv
singhasivanon
might
gam
eclampsia
embryos
campbell
prevailing
prolonged
stable
mechanism
treat
par
corresponding
discussion
infants
microbiol
jrm
2005
gravidity
drakeley
moderate
jb
america
831
gaye
krudsoos
second
sulphadoxine
versus
oduola
reduc
placenta
childbirth
reported
wc1e
vitro
randomised
plasmo
work
rakai
chandramohan2
it's
188
tau
observational
20261
conducted
abnormal
savis
arima
emerged
pro
three
bonell
specifically
army
settings
xue
was
schizonticides
ager
two
587
each
brabin
asitological
donation
africa
promise
isinin
reductase
schlagenhauf
assess
pharmacody
106
bia
203
progress
gynaecol
minor
chandramohan
dung
cameroonian
liem
hyaluronic
tropical
halofantrine
indications
weight
countries
borrmann
suggests
339
howard
268
full
1862
half
eijk
121
allergic
kain
limit
savanna
ried
available
lk
approved
hidden
spective
however
testing
ered
double
needy
italy
suppressive
patients
lurie
one
edwards
find
nausea
site
year
usa
fo
909
preventive
macheso
dar
among
relapses
considered
threatening
breckenridge
gastric
erythematous
kanyok
tg
te
146
807
monkeys
armstrong
mins
proportion
january
mgalula
sequential
dual
piper
undp
private
hastings
dou
poverty
dh
tm
disadvantages
still
pg
lj
medicines
will
maternal
infected
skin
sowumni
jchangalucha
211
parasitaemia
cytochrome
network
ethiopia
reac
ings
dihyroartem
future
quite
sample
cause
stefen
mcgreevy
very
skhivsg
infection
associations
insec
odds
pyronar
016
glaxosmithk
macrolide
requiring
popa
160
component
nosten
epub
artemisinin_pregnancy
vries
disparate
bined
dosing
adhesion
eh
p450
107
indeed
journal
cence
rash
nathan
lusaka
then
rd
coverage
tdr
734
converted
moo
2524
absorption
intermit
pd
prioritized
agnandji
direct
preterm
deficiency
urinary
fontenille
maubert
ragama
22who
blood
cambodia
folate
recrudes
antimicrob
weeks
zithromax
2199
keywords
ci
formula
due
itns
chongsuphajaisiddhi
dihy
mim
increased
asitic
515
1107
convened
food
unrelated
creativecommons
nahlen
thus
daily
similar
1995
nevirapine
evaluated
changes
nations
areas
described
felt
indicate
free
fac
situations
dha
license
evolution
azithromy
ited
others
pression
targett
transition
182
bj
monograph
chantra
815
here
metabo
ngugi
lancet
bs
herb
brughera
abdulla
den
abramowskye
given
yet
aged
pfizer
250
sudan
sanders
130
droartemisinin
principal
chu
isnin
zambia
ad
article
offset
between
yaounde
rattanapong
lives
duff
832
serum
keuter
asian
parts
peer
kk
jj
clin
winstanley
sumptive
424
acceptable
1402
oat
expert
female
artem
lation
proposes
attack
bwayo
guinea
wormwood
optimiza
acute
cd000386
689
anaemia
intermittent
dose
multinational
farrar
quinolinemethanol
trial
primaquine
727
eanmat
urgent
vention
gmp
cjm
predomi
women
www
looked
panda
801
russel
controlled
am
public
aina
exerts
beeson
agomo
rogerson
diseases
eastern
essentially
entry
programmes
1848
kumemura
children
rahman
nct00126971
598
day
equivalence
konsil
agents
115
nimol
auparakkitanon
commercially
2470
tol
1394
must
tri
body
scientist
characteristics
iw
shanks
2562
geneva
ac
using
single
since
advantage
1996
lan
concentrations
ing
darmstadt
simondon
239
122
embryotoxic
363
artesu
appeared
ramsey
tagbor
clarke
diagne
encouraging
inability
literature
widjaja
ception
fleming
colombo
522
nc
667
st
chlamydia
malarone
mutabingwa
clearance
nj
nota
rwanda
limited
manuscript
presumptive
ms
abuja
plasmodium
completed
within
ayisi
obtained
led
behrens
concluded
parzy
quashie
declare
consid
peshu
2004
mercially
20ipt
response
chapoomram
zurovac
kager
dizziness
because
parison
cof
travel
salaam
diovascular
madagascar
bank
resistant
toovey
fulfil
brouqui
cycloguanil
phy
wb
bull
ble
srivilairit
antagonist
uk
bmc
infections
abnormalities
wp
lapudrine
ramin
management
transmis
guidelines
slightly
chalermrut
meflo
cluster
retardation
milestones
mother
bangladesh
mcintosh
jf
industries
broad
malarious
looareesuwan
delivery
vary
relapse
358
331
ree
longer
737
survival
originally
phumra
used
lmvallely
vent
woman's
associ
when
responsible
background
incidence
deen
418
efforts
mai
627
ii
hence
placental
kiessling
485
debate
mode
richardson
folic
further
637
sign
preferable
base
kremsner
change
november
developing
535
summary
mittent
mali
institute
oped
kublin
1002
nct00274235
kebede
sa
tl
286
considerations
inadvertent
administration
krishna
rowe
mulation
promising
unknown
tors
gomes
names
adjusted
point
ial
proguanil
strategic
chemosup
eral
trimethoprim
bacterial
smoak
rw
kioy
000
g6pd
015
718
therapeutic
small
lell
duced
found
dihydroartem
association
targets
853
kerr
exposed
dabis
repeated
ureaplasma
cj
chlorpro
617
training
low
neuvonen
zaria
contraceptives
across
amj
through
theoretical
paul
poten
clear
take
truncated
loading
zinc
developed
purposes
occasions
duah
volunteers
licensing
transfer
school
1994
pl
bachang
1136
pe
tions
ss
read
introducing
once
eng
praevia
als
150
mannich
strategy
akintonwa
ndhlovu
abdool
heler
successful
present
dokomajilar
riley
sj
intervention
misore
genital
iv
recommends
co
susceptibility
368
oloo
d'alessandro
208
artemisia
291
uncom
114
either
common
intra
health
somalia
hodgson
vincenti
review
samewill
327
ogundahunsi
lshtm
vasdev
sutherland
clemens
temmerman
comparing
sone
changalucha1
interpreted
104
nct00164255
kuile
tent
ghatoura
mechanisms
watkins
lengeler
five
regimens
concerns
artesunate
cated
012
adult
amponsa
out
al
dunn
periph
sulf
hinari
stage
nt
266
size
estimates
dolecek
elucidating
publish
karita
dihydropteroate
693
street
strategies
enough
acting
en
helped
incardona
755
lines
cassels
doses
acid
safety
short
physiological
limbs
gonorrhoea
annua
sturm
mb
basri
seventy
tradi
169
cet
azithromycin
bl
2016
trachomatis
vanhauwere
edejer
vallely
190
hm
822
ak
briggs
rbminfosheet_9
browne
investigation
1782
humans
atpase
brahmbhatta
acceptability
els
murine
wiley
pharmacology
contribution
asp
head
intro
oue
malawi
o'meara
works
cda
sl
us
interventions
malariajournal
immune
gordon
ohrt
jg
ceptibility
longo
around
reproduction
not
years
brown
loss
po
chantelois
determinants
lungwena
droartemisnin
effectiveness
arowojolu
remain
mp
hiv
selection
gosling
123
daniel
travellers
severe
services
reduced
itching
times
jd
lee
standard
workers
courses
cisse
community
1009
roxithro
before
success
replication
privileged
imbalances
placen
team
inci
thomas
high
demonstrated
anthony
candi
first
immunol
idine
seriously
1985
candidate
sub
structure
mittal
pharmacodynamics
2003